Research Analysts Set Expectations for Stoke Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at HC Wainwright increased their FY2024 earnings per share estimates for Stoke Therapeutics in a report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($2.51) per share for the year, up from their previous estimate of ($2.62). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.57) EPS and FY2027 earnings at ($0.90) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million during the quarter, compared to analyst estimates of $3.70 million.

A number of other equities research analysts also recently commented on STOK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Monday. JPMorgan Chase & Co. upped their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 26th. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Finally, Wedbush increased their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $12.01 on Friday. The firm has a market cap of $625.96 million, a P/E ratio of -4.98 and a beta of 0.82. The firm has a 50 day simple moving average of $10.30 and a 200 day simple moving average of $6.72. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.40.

Insider Buying and Selling at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 5,126 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $13.20, for a total value of $67,663.20. Following the completion of the transaction, the general counsel now owns 2,598 shares of the company’s stock, valued at approximately $34,293.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. Insiders sold 3,622,741 shares of company stock valued at $41,935,115 in the last quarter. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Dorsey & Whitney Trust CO LLC bought a new position in shares of Stoke Therapeutics during the third quarter worth about $43,000. Sherbrooke Park Advisers LLC bought a new stake in Stoke Therapeutics in the 3rd quarter valued at about $48,000. SG Americas Securities LLC acquired a new stake in Stoke Therapeutics in the 3rd quarter valued at $53,000. Corton Capital Inc. acquired a new stake in shares of Stoke Therapeutics in the 3rd quarter worth about $58,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $64,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.